Business Context and Reporting Period
This Form 8-K Current Report was filed by cbdMD, Inc. on August 23, 2024. The filing details the entry into a Material Definitive Agreement involving the settlement of a trademark dispute and an amendment to existing debt instruments.
Key Financial Metrics and Transaction Details
The filing does not report standard financial metrics such as revenue, profit, cash flow, or margins for a specific period. Instead, it discloses specific transaction values related to a settlement agreement:
- Trademark Acquisition Cost: $100,000 paid immediately to Majik Medicine, LLC.
- Future Cash Obligations: $50,000 payable annually for four years (totaling $200,000 in additional payments).
- Equity Issuance: 75,000 shares of common stock issued immediately, with 50,000 additional shares to be issued on the one-year anniversary.
- Debt Instrument: Amendment to 8% Senior Secured Original Issue 20% Discount Convertible Promissory Notes issued on January 30, 2024.
Material Changes and Agreements
The Company entered into a Settlement, Purchase and Release Agreement with Majik Medicine, LLC to resolve a long-standing trademark dispute regarding the "CBD MD" mark. Key changes include:
- Trademark Resolution: cbdMD acquired the "CBD MD" Limited Mark, and both parties agreed to voluntarily dismiss pending litigation with prejudice.
- Debt Amendment: The Company amended its Convertible Notes and Security Agreement to pledge the acquired Limited Mark as a Permitted Lien and classify the future settlement payments as Permitted Indebtedness.
- Consulting Agreement: A five-year agreement was signed with Majik to provide nonexclusive consulting services to solicit Licensed Practitioners. Majik will receive a 15% commission on annual net sales increases from new sales to this specific customer base.
Outlook, Risks, and Management Commentary
Management believes securing the Limited Mark enhances the intellectual property portfolio, removes procedural impediments at the Trademark Trial and Appeal Board (TTAB), and avoids costly litigation. The consulting agreement targets a wholesale customer base the Company has previously been unable to exploit.
Risks and Contingencies:
- Reassignment Risk: If the Company fails to make the scheduled Additional Payments, the Limited Mark will be reassigned to Majik.
- Market Risks: Forward-looking statements are subject to risks including the wholesale customer base not accepting products, consumer hesitation to change, and the Company's inability to meet consulting agreement requirements.
Investor Verification Checklist
- Verify the total cash outflow commitment of $300,000 over five years for the trademark settlement.
- Confirm the dilution impact of the 125,000 total shares of common stock issued to Majik.
- Review the terms of the amended Convertible Notes to understand the lien status of the acquired trademark.
- Monitor the performance of the new consulting agreement regarding sales to Licensed Practitioners to assess the 15% commission liability.